AA Financial Advisors LLC Buys 46 Shares of Stryker Co. (NYSE:SYK)

AA Financial Advisors LLC raised its stake in shares of Stryker Co. (NYSE:SYK) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,547 shares of the medical technology company’s stock after purchasing an additional 46 shares during the quarter. AA Financial Advisors LLC’s holdings in Stryker were worth $1,277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cetera Investment Advisers increased its stake in Stryker by 2.5% in the second quarter. Cetera Investment Advisers now owns 89,948 shares of the medical technology company’s stock valued at $30,605,000 after acquiring an additional 2,220 shares during the last quarter. Sanctuary Advisors LLC bought a new position in shares of Stryker during the 2nd quarter valued at about $19,301,000. Centaurus Financial Inc. lifted its position in Stryker by 11.3% in the 2nd quarter. Centaurus Financial Inc. now owns 1,047 shares of the medical technology company’s stock worth $356,000 after buying an additional 106 shares during the last quarter. Appleton Partners Inc. MA boosted its stake in Stryker by 0.7% in the third quarter. Appleton Partners Inc. MA now owns 27,822 shares of the medical technology company’s stock worth $10,051,000 after buying an additional 182 shares in the last quarter. Finally, American National Bank & Trust grew its position in Stryker by 14.3% during the third quarter. American National Bank & Trust now owns 34,200 shares of the medical technology company’s stock valued at $12,355,000 after acquiring an additional 4,281 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $390.48 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market capitalization of $148.86 billion, a price-to-earnings ratio of 50.32, a PEG ratio of 2.68 and a beta of 0.95. The firm has a 50 day moving average price of $376.55 and a 200-day moving average price of $362.18. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter last year, the company posted $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.53 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.86%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday. Evercore ISI increased their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $416.40.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.